Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 1015-1021

  Van Herpen, Carla M L ^a   Bussink, Johan ^a   Van Der Kogel, Albert J ^a   Peeters, Wenny J M ^a   Van Der Voort, Robbert ^a   Van Schijndel, Anita ^a   De Wilde, Peter C M ^a   Adema, Gosse J ^a   De Mulder, Pieter H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hypoxia; ICAM 1; Interleukin 12; Perfusion; Proliferation; Vasculature

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BROXURIDINE; HOE 33342; INTERCELLULAR ADHESION MOLECULE 1; PIMONIDAZOLE; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOMATION; BLOOD FLOW; CANCER CONTROL; CELL HYPOXIA; CELL PROLIFERATION; COMPUTER ANALYSIS; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TISSUE PERFUSION; TUMOR VASCULARIZATION; XENOGRAFT;

ANIMALS; BODY WEIGHT; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL HYPOXIA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 17444419036     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Brunda MJ, Luistro L, Warrier RR et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993.
2. Nastala CL, Edington HD, McKinney TG et al: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1706, 1994.
3. Kobayashi M, Fitz L, Ryan M et al: Identification and purification of natural-killer cell stimulatory factor (Nksf), a cytokine with multiple biologic effects on human-lymphocytes. J Exp Med 170: 827-845, 1989.
4. Gately MK, Desai BB, Wolitzky AG et al: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147: 874-882, 1991.
5. Trinchieri G: Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84: 4008-4027, 1994.
6. Brunda MJ: Interleukin-12. J Leukoc Biol 55: 280-288, 1994.
7. Banks RE, Patel PM and Selby PJ: Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 71: 655-659, 1995.
8. Voest EE, Kenyon BM, O'Reilly MS et al: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581-586, 1995.
9. Sgadari C, Angiolillo AL and Tosato G: Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87: 3877-3882, 1996.
10. Sgadari C, Farber JM, Angiolillo AL et al: Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89: 2635-2643, 1997.
11. Kanegane C, Sgadari C, Kanegane H et al: Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 64: 384-392, 1998.
12. Tannenbaum CS, Tubbs R, Armstrong D et al: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161: 927-932, 1998.
13. Watanabe M, McCormick KL, Volker K et al: Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am J Pathol 150: 1869-1880, 1997.
14. Coughlin CM, Salhany KE, Wysocka M et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101: 1441-1452, 1998.
15. Gee MS, Koch CJ, Evans SM et al: Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res 59: 4882-4889, 1999.
16. Yao L, Sgadari C, Furuke K et al: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93: 1612-1621, 1999.
17. Yao L, Pike SE, Setsuda J et al: Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96: 1900-1905, 2000.
18. Dabrowska A, Giermasz A, Marczak M et al: Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. Anticancer Res 20: 391-394, 2000.
19. Duda DG, Sunamura M, Lozonschi L et al: Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 60: 1111-1116, 2000.
20. Cavallo F, Di Carlo E, Butera M et al: Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 59: 414-421, 1999.
21. Boggio K, Di Carlo E, Rovero S et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 60: 359-364, 2000.
22. Asselin-Paturel C, Lassau N, Guinebretiere JM et al: Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 5: 606-615, 1998.
23. van Herpen CM, Huijbens R, Looman M et al: Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human Interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in PBMCs. Clin Cancer Res 9: 2950-2956, 2003.
24. Arteel GE, Thurman RG, Yates JM et al: Evidence that hypoxia markers detect oxygen gradients in liver - pimonidazole and retrograde perfusion of rat-liver. Br J Cancer 72: 889-895, 1995.
25. Raleigh JA, Chou SC, Arteel GE et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiation Res 151: 580-589, 1999.
26. Westphal JR, vantHullenaar RGM, vanderLaak JAWM et al. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 76: 561-570, 1997.
27. Takei F: Inhibition of mixed lymphocyte-response by a rat monoclonal-antibody to a novel murine lymphocyte-activation antigen (Mala-2). J Immunol 134: 1403-1407, 1985.
28. Bussink J, Kaanders JHAM, Rijken PFJW et al. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts, effects of carbogen and nicotinamide. Radiother Oncol 50: 173-184, 1999.
29. Rijken PFJW, Bernsen HJJA, Peters JPW et al. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: A quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 48: 571-582, 2000.
30. Rijken PFJW, Bernsen HJJA, van der Kogel AJ. Application of an image-analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts. Microvascular Res 1950: 141-153, 1995.
31. Kindred, B. Nude Mice in immunology. Prog Allergy 26: 137-238, 1979.
32. Strasly M, Cavallo F, Geuna M et al: IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 766: 3890-3899, 2001.
33. Tasaki K, Yoshida Y, Maeda T et al: Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther 7: 247-254, 2000.
34. Ogawa M, Umehara K, Yu WG et al: A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res 59: 1531-1538, 1999.
35. Uekusa Y, Ogawa M, Gao P et al: The development of peritumoral stroma required for IL-12 induced tumor regression depends on the T cell/IFN-gamma-involving host-tumor interaction. Int J Oncol 16: 805-814, 2000.
36. Gee MS, Procopio WN, Makonnen S et al: Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 162: 183-193, 2003.
37. Lee JC, Kim DC, Gee MS et al: Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res 62: 747-755, 2002.